Yanyun Chen - Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA

基本信息

浏览量：22

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 54 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Time Spent in Glycaemic Control with Sustained Body Weight Reduction with Tirzepatide: A Post Hoc Analysis of the SURPASS Clinical Trial Programme

Brandon K Bergman,Julio Rosenstock,W Timothy Garvey,Rachel L Batterham,Yanyun Chen,Minzhi Liu, Palash Sharma,Chrisanthi A Karanikas,Vivian T Thieu

Diabetes, obesity & metabolismno. 6 (2025): 3223-3232

引用0浏览0WOS引用

Supplementary Table S3 from Overall Survival and Exploratory Biomarker Analyses of Abemaciclib Plus Trastuzumab with or Without Fulvestrant Versus Trastuzumab Plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients

Sara M. Tolaney,Shom Goel,Jorge Nadal,Hannelore Denys,Manuel Ruíz-Borrego,Lacey M. Litchfield,Jiangang Liu,Adams Kusi Appiah,Yanyun Chen,Andrea Varga

openalex（2024）

引用0浏览0引用

Supplementary Table S2 from Overall Survival and Exploratory Biomarker Analyses of Abemaciclib Plus Trastuzumab with or Without Fulvestrant Versus Trastuzumab Plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients

Sara M. Tolaney,Shom Goel,Jorge Nadal,Hannelore Denys,Manuel R. Borrego,Lacey M. Litchfield,Jiangang Liu,Adams K. Appiah,Yanyun Chen,Fabrice André

openalex（2024）

引用0浏览0引用

Supplementary Figure S1 from A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

Sara M. Tolaney,Solmaz Sahebjam,Emilie Le Rhun,Thomas Bachelot,Peter Kabos,Ahmad Awada,Denise Yardley,Arlene Chan,Pierfranco Conte,Véronique Diéras,Nancy U. Lin,Melissa Bear,Sonya C. Chapman,Zhengyu Yang,Yanyun Chen,Carey K. Anders

openalex（2023）

引用0浏览0引用

Overall Survival and Exploratory Biomarker Analyses of Abemaciclib Plus Trastuzumab with or Without Fulvestrant Versus Trastuzumab Plus Chemotherapy in HR+, HER2+Metastatic Breast Cancer Patients

Sara M. Tolaney,Shom Goel,Jorge Nadal,Hannelore Denys,Manuel R. Borrego,Lacey M. Litchfield,Jiangang Liu,Adams K. Appiah,Yanyun Chen,Fabrice Andre

Clinical Cancer Researchno. 1 (2023): 39-49

引用2浏览0WOS引用

Abemaciclib Plus Trastuzumab with or Without Fulvestrant Versus Trastuzumab Plus Standard-of-care Chemotherapy in Women with HR+, HER2+advanced Breast Cancer: Plain Language Summary of the Monarcher Study

Sara M. Tolaney,Shom Goel,Adams Kusi Appiah, Trish Huynh,Yanyun Chen,Fabrice Andre

FUTURE ONCOLOGY（2023）

引用1浏览0WOS引用

Nextmonarch Phase 2 Randomized Clinical Trial: Overall Survival Analysis of Abemaciclib Monotherapy or in Combination with Tamoxifen in Patients with Endocrine-Refractory HR + , HER2– Metastatic Breast Cancer

Hamilton Erika,Cortes Javier,Ozyilkan Ozgur,Chen Shin-Cheh,Petrakova Katarina,Manikhas Aleksey,Jerusalem Guy,Hegg Roberto,Huober Jens,Zhang Wei,Chen Yanyun,Martin Miguel

Breast Cancer Research and Treatment（2022）

引用7浏览0WOS引用

An Open Label, Randomized Phase 2 Trial Assessing the Impact of Food on the Tolerability of Abemaciclib in Patients with Advanced Breast Cancer

Lim Elgene,Boyle Frances,Okera Meena,Loi Sherene,Goksu Sema Sezgin,van Hal Gertjan,Chapman Sonya C.,Gable Jonathon Colby,Chen Yanyun,Price Gregory L.,Hossain Anwar M.,Gainford M. Corona,Ezquerra Meritxell Bellet

Breast Cancer Research and Treatment（2022）

引用1浏览0WOS引用

Abemaciclib in Combination with Pembrolizumab for HR+, HER2− Metastatic Breast Cancer: Phase 1b Study

Hope S. Rugo,Peter Kabos,J. Thad Beck,Guy Jerusalem,Hans Wildiers,Elena Sevillano,Luis Paz-Ares,Michael J. Chisamore,Sonya C. Chapman,Anwar M. Hossain,Yanyun Chen,Sara M. Tolaney

npj Breast Cancer（2022）

引用35浏览0WOSNATURE引用

Emonarcher: A Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Patients with HR+, HER2+, Node-Positive, High-Risk Early Breast Cancer

Sara M. Tolaney,Lesley Fallowfield,Peter A. Kaufman,Eva M. Ciruelos,Mary Corona Gainford,Yi Lu,Karla Hurt, Heather Ann Wasserstrom,Yanyun Chen,Shom Goel

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn